---
layout: post
title: "Mitigating Clinical Study Disruptions During Disasters and Public Health Emergencies; Public Meeting"
date: 2026-02-05 18:56:21 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-16544
original_published: 2023-08-03 00:00:00 +0000
significance: 8.00
---

# Mitigating Clinical Study Disruptions During Disasters and Public Health Emergencies; Public Meeting

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 03, 2023 00:00 UTC
**Document Number:** 2023-16544

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing a public meeting entitled "Mitigating Clinical Study Disruptions During Disasters and Public Health Emergencies." This public meeting will satisfy the mandate of the Food and Drug Omnibus Reform Act of 2022 (FDORA) to convene a public meeting on clinical study flexibilities initiated in response to the COVID-19 pandemic. The public meeting will be convened and supported by a cooperative agreement between FDA and the Clinical Trials Transformation Initiative (CTTI) to bring the clinical research community together to discuss a variety of topics related to mitigating disruptions of clinical studies of medical products during disasters and public health emergencies (PHEs). The meeting format will include presentations and panel discussions.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/03/2023-16544/mitigating-clinical-study-disruptions-during-disasters-and-public-health-emergencies-public-meeting)
- API: https://www.federalregister.gov/api/v1/documents/2023-16544

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
